Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

109 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Role of plaque proliferation in late lumen loss after directional coronary atherectomy.
Sumitsuji S, Katoh O, Tsuchikane E, Otsuji S, Tateyama H, Awata N, Kobayashi T. Sumitsuji S, et al. Circ J. 2002 Apr;66(4):362-6. doi: 10.1253/circj.66.362. Circ J. 2002. PMID: 11954950
[Pharmacoeconomic analysis of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy for the secondary prevention of coronary heart disease].
Sato S, Matsushita Y, Kobayashi T, Awata N. Sato S, et al. Nihon Eiseigaku Zasshi. 2004 Jul;59(3):335-41. doi: 10.1265/jjh.59.335. Nihon Eiseigaku Zasshi. 2004. PMID: 15359898 Clinical Trial. Japanese.
METHODS: Patients with a serum total cholesterol concentration of between 180 and 219 mg/dL at baseline were randomly assigned to two groups: the pravastatin group (n=54) and the group that did not receive cholesterol-lowering drugs (no-pravastatin group, n=66). ...
METHODS: Patients with a serum total cholesterol concentration of between 180 and 219 mg/dL at baseline were randomly assigned to two groups …
Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study.
Sanada S, Asanuma H, Koretsune Y, Watanabe K, Nanto S, Awata N, Hoki N, Fukunami M, Kitakaze M, Hori M. Sanada S, et al. Hypertens Res. 2007 Oct;30(10):913-9. doi: 10.1291/hypres.30.913. Hypertens Res. 2007. PMID: 18049022 Clinical Trial.
They were randomized into three groups with or without dipyridamole (Control: n=9; 75 mg/day: n=9; 300 mg/day: n=10) in addition to their original medications and were followed up for 1 year. ...
They were randomized into three groups with or without dipyridamole (Control: n=9; 75 mg/day: n=9; 300 mg/day: n=10) in …
A Single-Center, Open-Label, Randomized, Parallel-Group Study Assessing the Differences Between an Angiotensin II Receptor Antagonist and an Angiotensin-Converting Enzyme Inhibitor in Hypertensive Patients with Congestive Heart Failure: The Research for Efficacy of Angiotensin II Receptor Antagonist in Hypertensive Patients with Congestive Heart Failure Study.
Totsuka N, Awata N, Takahashi K, Yamamura H, Nakamura J, Tsuchikane E, Kobayashi Y, Nishibe A, Terai K. Totsuka N, et al. Curr Ther Res Clin Exp. 2003 Feb;64(2):81-94. doi: 10.1016/S0011-393X(03)00020-1. Curr Ther Res Clin Exp. 2003. PMID: 24944358 Free PMC article.
Transluminal percutaneous septal myocardial ablation in a patient with hypertrophic obstructive cardiomyopathy.
Tsuchikane E, Nakamura T, Yamazaki K, Kitano K, Izumi M, Otsuji S, Tateyama H, Awata N, Sakurai M, Kobayashi T. Tsuchikane E, et al. Jpn Circ J. 1998 Jul;62(7):537-40. doi: 10.1253/jcj.62.537. Jpn Circ J. 1998. PMID: 9707012
Calcium overload-induced myocardial damage caused by isoproterenol and by adriamycin: possible role of taurine in its prevention.
Azuma J, Hamaguchi T, Ohta H, Takihara K, Awata N, Sawamura A, Harada H, Tanaka Y, Kishimoto S. Azuma J, et al. Adv Exp Med Biol. 1987;217:167-79. doi: 10.1007/978-1-4899-0405-8_18. Adv Exp Med Biol. 1987. PMID: 3434418 No abstract available.
109 results
Jump to page
Feedback